2025年盐酸纳洛酮正版的价格是多少？

Naloxone hydrochloride is a powerful opioid receptor antagonist and is widely used in emergencies such as opioid overdose, alcohol poisoning, and post-anesthesia awakening. In 2025, the market price of naloxone hydrochloride will vary depending on dosage form, brand and regional differences. The imported genuine price of nasal spray (4mg/1mL) is approximately US$257 per box. Special groups such as pregnant women, children and those with liver and kidney dysfunction should use it with caution to avoid adverse reactions or withdrawal symptoms.

What is the price of genuine naloxone hydrochloride in 2025?

The price is greatly affected by dosage form, brand and purchasing channel. In 2025, the price of domestic injection dosage forms will drop significantly due to their inclusion in national centralized procurement, while imported nasal sprays will still maintain high prices.

Imported nasal spray prices

The genuine import price of naloxone hydrochloride nasal spray (Narcan, 4mg/0.1mL) produced by EMERGENT in Ireland is approximately US$257. This dosage form is easy to use by non-professionals, but the cost is high.

Price differences of different specifications

The dosage forms of naloxone hydrochloride include injection (0.4mg, 1mg, 2mg), freeze-dried powder injection (0.4mg, 1mg, 2mg, 4mg) and sublingual tablets (0.4mg). Injections are relatively low-priced due to their high degree of localization, while special dosage forms such as nasal sprays and automatic injection devices are more expensive.

The price of naloxone hydrochloride in 2025 will show a trend of low prices for domestic injections and high premiums for imported high-end dosage forms. Consumers can choose the appropriate dosage form according to their needs.

Usage and dosage of naloxone hydrochloride

Naloxone hydrochloride can be administered in various ways, including intravenous injection, intramuscular injection and nasal spray. The appropriate method needs to be selected according to the patient's condition.

Initial Dosage

The recommended initial dose of naloxone hydrochloride nasal spray for adult and pediatric patients is 1 spray (0.4 mg or 4 mg, depending on strength) administered through one nostril. The starting dose for intravenous injection is 0.4-0.8 mg, which can be repeated every 2-3 minutes until breathing is restored.

Repeated administration

If respiratory depression does not improve after the first administration, an additional dose can be added after 2-3 minutes. Nasal sprays are administered by changing nostrils, while injections can be administered intravenously or intramuscularly. For long-acting opioids (such as methadone), continuous monitoring is required to avoid recurrence of respiratory depression.

Dose adjustment for special circumstances

The use of naloxone by opioid dependent patients may induce withdrawal reactions, so the dose needs to be adjusted carefully. Patients with alcoholism can be given 0.8-1.2mg, and repeat 0.4-0.8mg after 1 hour. Postoperative anesthetic resuscitation usually requires a smaller dose (0.1-0.2 mg) to avoid severe pain.

The duration of action of naloxone hydrochloride is short (45-90 minutes), and the frequency of administration needs to be adjusted based on patient response to ensure sustained efficacy.

Naloxone Hydrochloride Medication for Special Populations

Different populations have different metabolisms and reactions to naloxone hydrochloride, and individualized medication is required to avoid adverse reactions.

Pregnant and lactating women

Naloxone can cross the placenta and may induce fetal withdrawal symptoms. Pregnant women should only use it when necessary. It is recommended for lactating women to suspend breastfeeding while taking the drug because the drug may be secreted through breast milk.

Children and newborns

The initial dose of intravenous injection in children is 0.01mg/kg, which can be increased to 0.1mg/kg if necessary. The usual dose for opioid suppression in neonates is 0.01 mg/kg, which requires monitoring for at least 24 hours.

Patients with hepatic and renal insufficiency

Naloxone is mainly metabolized in the liver. Patients with renal insufficiency may prolong the drug clearance time and need to adjust the dose. Patients with severe liver disease should use with caution to avoid drug accumulation.

When special groups use naloxone hydrochloride, their vital signs need to be closely monitored and the treatment plan adjusted in a timely manner to balance efficacy and safety.